Skip to product information

Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

Regular price $30.00 USD
Regular price $30.00 USD Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

Regular price $30.00
Regular price $30.00 Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
    View full details

    Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

    Include: 7 videos + 38 pdfs, size: 2.21 GB
    Target Audience: cardiologists, internists, primary care physicians
    Information:

    This course provides comprehensive training for healthcare professionals in the advanced management of heart failure. The curriculum is designed to equip participants with the latest knowledge and skills necessary to optimize patient outcomes through innovative therapeutic strategies and interventions.

    After completing this course, participants will be able to

    • Apply appropriate strategies to optimize use of current and novel drug therapy of heart failure with reduced left ventricular ejection fraction
    • Describe how to utilize medical devices and surgical therapies in the care of heart failure patients
    • Discuss the clinical profile of heart failure and differentiate between reduced and preserved ejection fraction patients
    • Discuss the latest findings concerning pharmacological approaches to heart failure with midrange or preserved ejection fraction
    • Employ current therapeutic strategies for cardiac amyloid and hypertrophic cardiomyopathy
    • Identify options for electrophysiological interventions to address risk of sudden death and atrial arrhythmias in patients with heart failure

    Who Should Attend?


    The course is directed to physicians, physician assistants, pharmacists, nurse practitioners, nurses, and all healthcare providers with an interest in treating and managing patients with heart failure.

     

    Topics:
    • Agenda.pdf
      June 6 Advanced evaluation of the breathless patient.pdf
      June 6 AF ablation and the pulsed field era.pdf
      June 6 Arrhythmogenic cardiomyopathies and genetic testing.pdf
      June 6 Breakthroughs in obesity-related HFpEF.pdf
      June 6 Cardiac contractility modulation.pdf
      June 6 Current and emerging device-based therapies for HFpEF.pdf
      June 6 Educating and engaging the patient of tomorrow.pdf
      June 6 GDMT optimization across the inpatient-outpatient domain.pdf
      June 6 Harnessing tech for GDMT optimization and readmission reduction.pdf
      June 6 Harnessing the heart team for GDMT equity.pdf
      June 6 HF STATS The changing face of heart failure.pdf
      June 6 Lessons learnt for diverse HF trial recruitment.pdf
      June 6 New insights into HFpEF mechanisms.pdf
      June 6 Novel therapies for cardiomyopathies.pdf
      June 6 Remote monitoring in the “AI era”- Leveraging new devices and algorithms.pdf
      June 6 Remote monitoring the “old school” way- Weights, vitals and symptoms.pdf
      June 6 Session 1 – Updates in HF Epidemiology and Population Health.mp4
      June 6 Session 2 – HFrEF and EP Innovations.mp4
      June 6 Session 3 – HFpEF and Pulmonary Hypertension.mp4
      June 6 Session 4A – Meet the Clinical Trialists (Concurrent Session).mp4
      June 6 The future of remote HF and EP monitoring.pdf
      June 6 The LAA and controversies in anticoagulation.pdf
      June 6 The next frontier- earlier diagnosis and treatment of HF.pdf
      June 6 The next generation HFrEF therapies.pdf
      June 6 Trials and tribulations in valvular interventions.pdf
      June 6 Ventricular tachycardia in patients with HFrEF.pdf
      June 6 What’s new in pulmonary hypertension.pdf
      June 7 A positive PET scan- What comes next.pdf
      June 7 Collapse to comeback- Improving outcomes after cardiac arrest.pdf
      June 7 DanGer ahead- Seeking an evidence base for shock management.pdf
      June 7 Evolutions in organ preservation and transportation.pdf
      June 7 Fixing the flow- Revascularization for the high-risk patient.pdf
      June 7 Getting shock right- Managing the right ventricle.pdf
      June 7 HCM in the era of myosin inhibition.pdf
      June 7 LVADs in a Transplant World.pdf
      June 7 Managing MCS at a non-transplant center.pdf
      June 7 Managing TTR cardiac amyloidosis in 2025.pdf
      June 7 Multidisciplinary cardiac care during pregnancy.pdf
      June 7 Post-heart transplant outcomes and management innovations.pdf
      June 7 Session 1 – Cardiomyopathies (amyloid, HCM, Sarcoid) and HFrEF.mp4
      June 7 Session 2 – MCS and TX.mp4
      June 7 Session 3 – Cardiogenic shock and critical care.mp4
      June 7 The next generation of LVADs and trials.pdf
      June 7 Transplant and VAD options in congenital conditions.pdf